You are here:
CTSPedia
>
CTSpedia Web
>
StatGraphHome
>
AllGraphicalEntries
(24 Oct 2013,
MatSoukup
)
E
dit
A
ttach
Tags:
tag this topic
create new tag
,
view all tags
,
tagging instructions
All Graphics Form Entries
Return to Statistical Graphics Home
All Graphs
Graph Types
Software Program
All Graphs
Title
Contributor/Email
Reference Image
Graph Type
Basic Survival Plot
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Survival Plot
Boxplot of Two Treatment Groups
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Boxplot
Change from Baseline by Baseline: Categorical QTc Analysis
Rich Anziano (
richard.j.anziano@pfizer.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Scatterplot
Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal
Robert Gordon (
rgordon2@its.jnj.com
)
Depicting Phase 2 Efficacy Results
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Diagnostic Plot of Linear Model
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Distribution of Alanine Aminotransferase (ALT) by Time and Treatment
Robert Gordon (
rgordon2@its.jnj.com
)
Boxplot
Dotplot of Primary SOC
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
Dotplot
EG QTc Longitudinal Trend
jianminlong@merck.com
Line Plot,
Scatterplot
, Other
Efficacy Across Sites
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Efficacy by Subgroup
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Efficacy of T4N5 The Lancet Data - Code Expands
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Forest Plot of Hazard Ratios by Patient Subgroups
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
Forest Plot
Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit
Robert Gordon (
rgordon2@its.jnj.com
)
HPA Axis Suppression
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Heat map
max.2.cherny@gsk
.com
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
Individual QTc display
A. Paredes,
Antonio.Paredes@fda.hhs
.gov
Max Cherny:
Max2Cherny@gsk.com
Lab Parameter Shift Plots, Baseline vs. Study
Robert Gordon (
rgordon2@its.jnj.com
)
Scatterplot
Lab Shift Plots: Baseline versus Maximum
Susan Duke (
susan.p.duke@gsk.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Scatterplot
Liver Function Tests by Trial Day: At Risk Subjects
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot
Liver Test Safety Panel Over Time, Baseline vs. On-study
Robert Gordon (
rgordon2@its.jnj.com
)
Scatterplot
Local Reactions over Time
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot
Most Frequent On-Therapy AE Sorted by Risk Difference
FrankHarrell
Dotplot
P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level
Qi Jiang (email:
Qjiang@amgen.com
)
SAS code contributed by Haijun Ma and Jun Wei
Volcano Plots
Profile Plot: Mean QTc by Time and Treatment
Rich Anziano (
richard.j.anziano@pfizer.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Line Plot
QT Correction Comparison
R.J. Anziano,
Richard.J.Anziano@Pfizer.com
Scatterplot
Reports by SOC
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin
Robert Gordon (
rgordon2@its.jnj.com
)
Scatterplot
Scatterplot Conditioned on Race
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Scatterplot w/ Density and Smoothed Regression
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Sensitivity Analysis of Missing Data
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Perspective Plot
Summary of All EG Parameters
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Systolic Blood Pressure (Main Profiles)
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Line Plot
Time Course of Lab Test Values, Individual Subject
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot
Time to AE Occurrence
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Survival Plot
Number of topics:
36
Return to Top
Graph Types
Graph Type
Title
Contributor/Email
Reference Image
Reports by SOC
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Heat map
max.2.cherny@gsk
.com
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
Summary of All EG Parameters
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Individual QTc display
A. Paredes,
Antonio.Paredes@fda.hhs
.gov
Max Cherny:
Max2Cherny@gsk.com
Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit
Robert Gordon (
rgordon2@its.jnj.com
)
Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal
Robert Gordon (
rgordon2@its.jnj.com
)
Boxplot
Boxplot of Two Treatment Groups
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Boxplot
Distribution of Alanine Aminotransferase (ALT) by Time and Treatment
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot,
Scatterplot
, Other
EG QTc Longitudinal Trend
jianminlong@merck.com
Perspective Plot
Sensitivity Analysis of Missing Data
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Survival Plot
Time to AE Occurrence
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Survival Plot
Basic Survival Plot
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Volcano Plots
P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level
Qi Jiang (email:
Qjiang@amgen.com
)
SAS code contributed by Haijun Ma and Jun Wei
Dotplot
Most Frequent On-Therapy AE Sorted by Risk Difference
FrankHarrell
Dotplot
Dotplot of Primary SOC
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
Forest Plot
Forest Plot of Hazard Ratios by Patient Subgroups
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
Line Plot
Liver Function Tests by Trial Day: At Risk Subjects
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot
Time Course of Lab Test Values, Individual Subject
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot
Systolic Blood Pressure (Main Profiles)
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Line Plot
Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time
Robert Gordon (
rgordon2@its.jnj.com
)
Line Plot
Profile Plot: Mean QTc by Time and Treatment
Rich Anziano (
richard.j.anziano@pfizer.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Scatterplot
Scatterplot Conditioned on Race
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Liver Test Safety Panel Over Time, Baseline vs. On-study
Robert Gordon (
rgordon2@its.jnj.com
)
Scatterplot
Depicting Phase 2 Efficacy Results
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Lab Shift Plots: Baseline versus Maximum
Susan Duke (
susan.p.duke@gsk.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Scatterplot
Change from Baseline by Baseline: Categorical QTc Analysis
Rich Anziano (
richard.j.anziano@pfizer.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
Scatterplot
Efficacy Across Sites
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Efficacy by Subgroup
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Lab Parameter Shift Plots, Baseline vs. Study
Robert Gordon (
rgordon2@its.jnj.com
)
Scatterplot
Local Reactions over Time
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Efficacy of T4N5 The Lancet Data - Code Expands
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Diagnostic Plot of Linear Model
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin
Robert Gordon (
rgordon2@its.jnj.com
)
Scatterplot
Scatterplot w/ Density and Smoothed Regression
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Scatterplot
QT Correction Comparison
R.J. Anziano,
Richard.J.Anziano@Pfizer.com
Scatterplot
HPA Axis Suppression
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Number of topics:
36
Return to Top
Software Program
Title
Graph Displayed
Contributor/Email
Software Program
Basic Survival Plot
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Boxplot of Two Treatment Groups
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Change from Baseline by Baseline: Categorical QTc Analysis
Rich Anziano (
richard.j.anziano@pfizer.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
R
Cumulative Incidence for Alanine Aminotransferase (ALT): Elevations > 3 Times the Upper Limit of Normal
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Depicting Phase 2 Efficacy Results
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Diagnostic Plot of Linear Model
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Distribution of Alanine Aminotransferase (ALT) by Time and Treatment
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Dotplot of Primary SOC
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
R, SAS
EG QTc Longitudinal Trend
jianminlong@merck.com
SAS
Efficacy Across Sites
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Efficacy by Subgroup
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Efficacy of T4N5 The Lancet Data - Code Expands
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Forest Plot of Hazard Ratios by Patient Subgroups
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
SAS
Frequency Plot of the Change from Baseline in Alanine Aminotransferase by Visit
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
HPA Axis Suppression
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Heat map
max.2.cherny@gsk
.com
Sanjay Matange (email:
Sanjay.Matange@sas.com
)
R, SAS
Individual QTc display
A. Paredes,
Antonio.Paredes@fda.hhs
.gov
Max Cherny:
Max2Cherny@gsk.com
R
Lab Parameter Shift Plots, Baseline vs. Study
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Lab Shift Plots: Baseline versus Maximum
Susan Duke (
susan.p.duke@gsk.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
SAS, other
Liver Function Tests by Trial Day: At Risk Subjects
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Liver Test Safety Panel Over Time, Baseline vs. On-study
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Local Reactions over Time
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Mean (and Mean Difference) of ALT (Alanine Aminotransferase) by Treatment : Profile Over Time
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Most Frequent On-Therapy AE Sorted by Risk Difference
FrankHarrell
R, SAS
P-risk (Risk Difference) Plot of Treatment Emergent Adverse Events at PT Level
Qi Jiang (email:
Qjiang@amgen.com
)
SAS code contributed by Haijun Ma and Jun Wei
SAS
Profile Plot: Mean QTc by Time and Treatment
Rich Anziano (
richard.j.anziano@pfizer.com
)
Max Cherny (
Max.2.Cherny@gsk.com
)
R, SAS
QT Correction Comparison
R.J. Anziano,
Richard.J.Anziano@Pfizer.com
Reports by SOC
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Scatter Plot of Maximum Transaminase versus Maximum Total Bilirubin
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Scatterplot Conditioned on Race
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Scatterplot w/ Density and Smoothed Regression
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Sensitivity Analysis of Missing Data
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Summary of All EG Parameters
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
SAS
Systolic Blood Pressure (Main Profiles)
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
R
Time Course of Lab Test Values, Individual Subject
Robert Gordon (
rgordon2@its.jnj.com
)
SAS
Time to AE Occurrence
Mat Soukup (email:
Mat.Soukup@fda.hhs.gov
)
Max Cherny (
Max.2.Cherny@gsk.com
)
R, SAS
Number of topics:
36
Return to Top
Return to Statistical Graphics Home
E
dit
|
A
ttach
|
P
rint version
|
H
istory
: r25
<
r24
<
r23
<
r22
<
r21
|
B
acklinks
|
R
aw View
|
Ra
w
edit
|
M
ore topic actions
Topic revision: r25 - 24 Oct 2013 - 11:34:48 -
MatSoukup
CTSpedia
Log In
Webs on CTSpedia
CTSpedia
Main
ResearchEthics
Sandbox
System
Recent Changes
Help
Copyright &© by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding CTSPedia?
Send feedback